T. Rowe Price Associates’s Summit Therapeutics SMMT Stock Holding History

T. Rowe Price Associates’s Portfolio SMMT Stock Details SMMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$157M	Sell	8,277,859 -1,093,556	-12%	-$17.7M	0.02%	517
2025 Q4	$164M	Buy	9,371,415 +4,832,592	+106%	+$90.9M	0.02%	520
2025 Q3	$93.8M	Buy	4,538,823 +633,675	+16%	+$15.4M	0.01%	637
2025 Q2	$83.1M	Sell	3,905,148 -2,652,656	-40%	-$60.5M	0.01%	611
2025 Q1	$127M	Sell	6,557,804 -123	-0%	-$2.47K	0.02%	514
2024 Q4	$117M	Buy	6,557,927 +1,118,270	+21%	+$21.7M	0.01%	541
2024 Q3	$119M	Buy	5,439,657 +3,397,557	+166%	+$47.5M	0.01%	529
2024 Q2	$15.9M	Buy	2,042,100 +2,008,955	+6,061%	+$10.9M	﹤0.01%	1013
2024 Q1	$138K	Buy	33,145 +5,139	+18%	+$20.4K	﹤0.01%	2716
2023 Q4	$74K	Buy	28,006 +1,059	+4%	+$2.18K	﹤0.01%	2760
2023 Q3	$51K	Buy	26,947 +3,435	+15%	+$6.55K	﹤0.01%	2777
2023 Q2	$60K	Buy	+23,512	New	+$42.9K	﹤0.01%	2781

Other funds holding SMMT

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

T. Rowe Price Associates's SMMT Position: Q1 2026 in Review

T. Rowe Price Associates reduced its Summit Therapeutics (SMMT) stake by 12% in Q1 2026, selling an estimated $17.7M and leaving 8,277,859 shares worth $157M. The position accounts for 0.02% of the portfolio, ranked #517.

T. Rowe Price Associates first reported a position in SMMT in Q2 2023 and has held it in 12 quarters since. The position peaked at $164M in Q4 2025. 222 funds tracked by Wall St. Rank hold SMMT as of Q1 2026.

T. Rowe Price Associates held 8,277,859 shares of Summit Therapeutics worth $157M as of Q1 2026.
T. Rowe Price Associates sold 1,093,556 Summit Therapeutics shares in Q1 2026, an estimated $17.7M.
Summit Therapeutics made up 0.02% of T. Rowe Price Associates's portfolio in Q1 2026, its #517 holding.
T. Rowe Price Associates first reported a position in Summit Therapeutics in Q2 2023 and has held it in 12 quarters since.
T. Rowe Price Associates's Summit Therapeutics position peaked at $164M in Q4 2025.
222 funds tracked by Wall St. Rank held Summit Therapeutics as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.